Related Experiment Video

Updated: Dec 28, 2025

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.7K

Modulation of SERCA in Patients with Persistent Atrial Fibrillation Treated by Epicardial Thoracoscopic Ablation: The

Celestino Sardu1,2, Gaetano Santulli3,4, Germano Guerra5

  • 1Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.

Journal of Clinical Medicine
|February 22, 2020
PubMed

Insights

Sarcoplasmic Endoplasmic Reticulum Calcium ATPase (SERCA) levels may predict atrial fibrillation (AF) recurrence after epicardial ablation. Increased SERCA in responders suggests it could be a therapeutic target for improving ablation outcomes.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Biochemistry

Background:

  • Reduced Sarcoplasmic Endoplasmic Reticulum Calcium ATPase (SERCA) levels are observed in patients with atrial fibrillation (AF).
  • SERCA levels are hypothesized to predict treatment response to epicardial ablation for AF.

Purpose of the Study:

  • To evaluate AF recurrence rates after epicardial thoracoscopic ablation.
  • To assess Sarcoplasmic Endoplasmic Reticulum Calcium ATPase (SERCA) levels in patients undergoing ablation for persistent AF.

Main Methods:

  • A prospective, multicenter observational study was conducted.
  • 27 patients with persistent AF received epicardial thoracoscopic pulmonary vein isolation between October 2014 and June 2016.

Main Results:

  • Fifteen responders showed no AF recurrence at one-year follow-up.
  • Responders had reduced inflammatory cytokines, B type natriuretic peptide (BNP), and increased SERCA levels compared to baseline and non-responders.
  • AF duration, Left Atrium Volume (LAV), BNP, and SERCA levels predicted AF recurrence.

Conclusions:

  • Baseline SERCA levels may predict the success of epicardial ablation for persistent AF.
  • Epicardial ablation increased SERCA levels in patients who responded to the treatment.
  • SERCA presents a potential novel therapeutic target to enhance the efficacy of epicardial ablative procedures.
Abstract

Keywords:
SERCAcalcium channelsepicardial ablationpersistent atrial fibrillation

More Related Videos

Robotic Ablation of Atrial Fibrillation11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

20.0K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.8K

Related Concept Videos

Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
334
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
380
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
302
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
2.3K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
372
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
828